loading page

The efficacy and safety of up to 24 weeks of triptorelin therapy following conservative surgery in patients with deep infiltrating endometriosis (DIE): a multicentre, prospective, non-interventional study in China
  • +7
  • Li-bo Zhu,
  • Zheng Guan,
  • Yan Huang,
  • Keqin Hua,
  • Liguo Ma,
  • Jian Zhang,
  • Dazhen Yang,
  • Valerie Perrot,
  • Hongbo Li,
  • Xinmei Zhang
Li-bo Zhu
Womens Hospital, Zhejiang University School of Medicine
Author Profile
Zheng Guan
Chinese PLA General Hospital, Beijing, China
Author Profile
Yan Huang
The Second Affiliated Hospital of Army Medical University
Author Profile
Keqin Hua
Obstetrics and Gynecology Hospital of Fudan University
Author Profile
Liguo Ma
Shenzhen People’s Hospital, Guangdong Province, China
Author Profile
Jian Zhang
International Peace Maternity and Child Health Hospital of the China Welfare Institute, Shanghai, China
Author Profile
Dazhen Yang
Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu Province, China
Author Profile
Valerie Perrot
Ipsen, Boulogne-Billancourt, France
Author Profile
Xinmei Zhang
Womens Hospital, Zhejiang University School of Medicine
Author Profile

Abstract

OBJECTIVE: To evaluate the efficacy and safety of up to 24 weeks of triptorelin treatment after conservative surgery for deep infiltrating endometriosis (DIE). DESIGN: Multicentre, prospective, non-interventional. SETTING: 18 tertiary hospitals in China. POPULATION: Premenopausal women aged ≥ 18 years treated with triptorelin 3.75 mg once every 28 days for up to 24 weeks after conservative surgery for DIE METHODS: Endometriosis symptoms were assessed, using a visual analogue scale (0–10 cm) or numerical range (0–10), at baseline (pre-surgery) and routine visits 3, 6, 9, 12, 18 and 24 months after surgery. MAIN OUTCOME MEASURES: Change in symptom intensity over time. RESULTS: A total of 384 women were analysed (mean [SD] age, 33.4 [6.2] years). Scores for all symptoms assessed (pelvic pain, dysmenorrhoea, ovulation pain, dyspareunia, menorrhagia, metrorrhagia and gastrointestinal and urinary symptoms) decreased from baseline over 24 months. Cumulative improvement rates in pelvic pain, dysmenorrhoea, ovulation pain and dyspareunia were 74.4%, 83.6%, 55.1% and 66.9%, respectively. The 24-month cumulative recurrence rate (≥ 1 symptom) was 22.2%. The risk of symptom recurrence was higher in patients with ≥ 2 versus 1 lesion (odds ratio [OR] 2.539; 95% CI: 1.458–4.423; p = 0.001) and patients with moderate (OR 5.733; 95% CI: 1.623–20.248; p = 0.007) or severe (OR 8.259; 95% CI: 2.449–27.851; p = 0.001) pain versus none/mild pain. Triptorelin was well tolerated. CONCLUSIONS: Triptorelin after conservative surgery for DIE improved symptoms over 24 months of follow up. FUNDING: Sponsored by Ipsen